HIGHLIGHTS
SUMMARY
The safety of long-term imatinib therapy is well established compared to other front-line options, such as dasatinib 100 mg once a day (28% of patients will experience pleural effusions by 5 years ), nilotinib 300 mg twice a day (13% of the patients will develop cardiovascular events by 5 years ) or bosutinib 400 mg daily (7.8% diarrhea grade 3, 19% increased ALT ). The resulting mean daily dose of imatinib was, as expected, higher in the TDM arm (603 mg daily at 12 months) compared to 391 mg daily in the control arm . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.